NEW BRUNSWICK -- Johnson & Johnson said Boston Scientific will pay the company $1.7 billion to settle two suits related to patents for stents. Boston Scientific Corp. will pay Johnson & Johnson's ...

Boston Scientific has announced the European market launch of the PROMUS Element Plus stent, which incorporates platinum chromium allow and features a catheter delivery system.

Rockville, MD and Detroit, MI - The US Food and Drug Administration (FDA) has approved the Promus ElementPluseverolimus-eluting chromium platinum coronary stent (Boston Scientific), a thinner ...

Bridgewater-based Cordis Corp. said Wednesday it would stop development of one stent and discontinue the manufacture of two more stents by the end of 2011 as part of a restructuring plan.

What’s in a stent name? Everything, it turns out, in the case of the country’s two newest drug-coated stents. The U.S. Food and Drug Administration this week approved for use the new Xi… ...

The radiologist, Bruce Saffran, filed a lawsuit in 2007, accusing Cordis of infringing a patent he obtained in 1997 to make its Cypher brand drug-eluting stents. A jury ruled for Saffran in 2011.

SAN FRANCISCO, California — A biolimus-eluting coronary stent lined with a biodegradable polymer (Nobori, Terumo) was statistically noninferior to an everolimus-eluting stent (Xience V/Promus ...

Natick-based Boston Scientific has received approval from the FDA to market its Promus brand stent system in vessels as small as 2.25 millimeters in diameter.Boston Scientific plans to begin ...

The company already sells a drug-eluting stent system in the country. The Japanese Ministry of Health, Labor and Welfare approved the PROMUS stent system, allowing the medical device company to ...

Medical device maker Boston Scientific said Monday it received European marketing approval for its latest drug-coated stent technology, which prevents blocked arteries. IE 11 is not supported.

Cordis, a unit of Johnson & Johnson is seeking an expanded indication for its SMART self-expanding stent, and the device performed well in patients with obstructive superficial femoral artery ...